P. L. Haslam (London, United Kingdom), C. Albera (Turin, Italy)
Candidate surrogate markers for COPD identified by differential gene expression
P. Couttet, P. C. Masdin, C. L. Clayton, V. M. Pinto-Plata, B. R. Celli, T. J. Eichholtz (Stevenage, ; Stevenage, United Kingdom; Boston, United States Of America)
|  |
Elevation of plasma cystatin C levels in patients with COPD
T. Nakajima, H. Nakamura, H. Tateno, N. Minematsu, S. Fujishima, K. Yamaguchi (Tokyo, Japan)
| |
Dyspnoea in healthy smokers:its evaluation by cardiopulmonary exercise testing and bronchial cellularity
G. Bruni, F. Romamo, A. Mancuso, M. I. Scarlato, S. Barbera, N. P. Scarpelli (Cosenza, Italy)
| |
Effects of one year smoking cessation on inflammation in induced sputum of smokers with and without COPD
B. W. M. Willemse, N. H. T. ten Hacken, B. Rutgers, I. G. A. T. Leegte, D. S. Postma, W. Timens (Groningen, The Netherlands)
| |
The cellular composition and macrophage phenotypes in induced sputum in relation to tobacco smoking and bronchial constriction
J. J. Domagala-Kulawik, M. Maskey-Warzechowska, I. Kraszewska, R. Chazan (Warsaw)
| |
Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human
A. Boutten, M. Bonay, S. Laribe, G. Leseche, Y. Castier, V. Leçon-Malas, M. Fournier, G. Durand, M. Aubier, M. Dehoux, B. Crestani (Paris, Clichy, France)
| |
Inflammatory markers in sputum of patients with cough variant asthma
D. A. De Diego, E. Martinez, M. Perpiñá, M. L. Nieto, L. Compte, V. Macián (Valencia, Spain)
| |
Bronchoalveolar lavage in severe persistent asthma
M. Terl, P. Panzner, M. Pesek, J. Hanzlíková (Plzen, Czech Republic)
| |
Do leukotriene antagonists reduce eosinophil numbers in induced sputum from asthmatic patients as a consequence of increased apoptosis induction?
A. Lawrie, G. Douglas, G. M. Walsh (Aberdeen, United Kingdom)
| |
Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia
E. Majewska, M. Kasielski, P. Bialasiewicz, D. Nowak (Lodz, Poland)
| |
Exocytosis of matrix metalloproteinases (MMPs) by pulmonary and systemic polymorphonuclear neutrophils (PMN) in hospital acquired pneumonia (HAP)
C. M. Hartog, J. A. Wermelt, W. Eichler, K. Dalhoff, J. Braun (Luebeck, Germany)
| |
Level of Transforming Growth Factor-β in bronchoalveolar lavage fluid after lung transplantation
E. Udry, B. Carnal, J. D. Aubert (Lausanne, Switzerland)
| |
Elevated TGF- b1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer
J. J. Domagala-Kulawik, G. G. Hoser, A. A. Safianowska, H. H. Grubek Jaworska, R. R. Chazan (Warsaw, Poland)
| |
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines
O. Hataji, E. C. Gabazza, H. Yuda, H. Fujimoto, Y. Adachi, O. Taguchi (Tsu, Japan)
| |
Upregulation of expression of membrane apoptosis signals by bronchoalveolar lavage cells in patients with pulmonary sarcoidosis
B. M. Chen, Z. H. Tong, J. Guzman, U. Costabel (Germany)
| |
Increased production of caspase-1 by alveolar macrophages in patients with pulmonary sarcoidosis
Z. H. Tong, B. M. Chen, J. Guzman, U. Costabel (Essen, Bochum, Germany)
| |
Can the study of BAL protein composition help to characterize the type of immune response in ILD?
P. Rottoli, M. Perari, A. Fossi, N. Nikiforakis, L. Bini, V. Pallini, B. Magi (Siena, Italy)
| |
Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease
H. Fujimoto, E. C. Gabazza, O. Hataji, H. Yuda, Y. Adachi, O. Taguchi (Tsu, Japan)
| |
Morphological and immunohistochemical characteristics of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF)
T. Y. Manuilova, E. A. Kogan, E. N. Popova, D. A. Golbin (Moscow, Russia)
| |
Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies
T. E. Gembitskaya, I. B. Bondarenko, L. N. Novikova, N. Muhin (St.-Petersburg, Moscow, Russia)
| |